Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Gross Profit | -3.5M | 5.2% |
Cost of Revenue | 3M | 5.4% |
Operating expense | 18M | 91.7% |
Net Income | -17M | 108.5% |
EBITDA | -18M | 92.3% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 126M | 10.8% |
Total Liabilities | 28M | 0.5% |
Total Equity | 98M | 13.3% |
Shares Outstanding | 59M | 0% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | -13M | 32.6% |
Cash from investing | -18M | 40% |
EPS
Financial Highlights for Aldeyra Therapeutics in Q2 '24
Gross Profit stood at -3.5M, marking a 5.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 3M, a -5.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 18M, showing a 91.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -17M, showing a -108.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -18M, showing a -92.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Aldeyra Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.